NuGen Medical Devices Inc

As of June 30, 2026, NuGen Medical Devices Inc carries a market capitalization of 3.59M, placing it among publicly traded companies globally. Its enterprise value stands at 14.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, NuGen Medical Devices Inc has 227.04M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 39.11, and the price-to-book ratio stands at -0.34.

These figures are as of June 30, 2026. The EV/Sales ratio of 159.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 14.64M versus a market cap of 3.59M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, NuGen Medical Devices Inc maintains a current ratio of 0.39, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -108.81, indicating conservative leverage, while an interest coverage ratio of -2.56 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -145.42, reflecting losses generated across the asset base. Inventory turnover of 0.19 indicates how many times NuGen Medical Devices Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, NuGen Medical Devices Inc recorded 27,331.96 in income tax expense. The company reported a pretax loss of -5.80M and -5.97M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on August 6, 2026, NuGen Medical Devices Inc's stock has declined approximately 68.57% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

Over the twelve months ended June 30, 2026, NuGen Medical Devices Inc generated 91,723.29 in revenue and converted that into -5.97M in net income, yielding earnings per share of -0.03. EBITDA reached -5.56M, while operating income came in at -2.70M.

As of June 30, 2026, NuGen Medical Devices Inc holds 432,202.85 in cash and equivalents against 11.48M in total debt, resulting in a net debt position of 11.05M. Total book value stands at -10.56M, with working capital of -1.42M providing operational flexibility.

NuGen Medical Devices Inc produced -2.58M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -360,829.27 in capital expenditures, free cash flow totaled -2.95M - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, NuGen Medical Devices Inc posted a gross margin of 47.83, reflecting its pricing power and cost economics. The operating margin of -2,941.78 and net profit margin of -6,514.13 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -82.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to NuGen Medical Devices Inc shareholders.

NuGen Medical Devices Inc's most recent stock split took place on November 8, 2021 with a 2:1 split ratio.

As of June 30, 2026, NuGen Medical Devices Inc has an Altman Z-Score of -37.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.